위궤양에 대한 레바프라잔 정제의 제3상 임상시험
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장린 | - |
dc.contributor.author | 주상언 | - |
dc.contributor.author | 정인식 | - |
dc.contributor.author | 박수헌 | - |
dc.contributor.author | 김성국 | - |
dc.contributor.author | 최석렬 | - |
dc.contributor.author | 송근암 | - |
dc.contributor.author | 함기백 | - |
dc.contributor.author | 이용찬 | - |
dc.contributor.author | 김현수 | - |
dc.contributor.author | 김태년 | - |
dc.contributor.author | 최석채 | - |
dc.contributor.author | 설상영 | - |
dc.contributor.author | 유종선 | - |
dc.contributor.author | 김동준 | - |
dc.contributor.author | 이진 | - |
dc.contributor.author | 최호순 | - |
dc.contributor.author | 이정은 | - |
dc.contributor.author | 송근석 | - |
dc.contributor.author | 문병석 | - |
dc.date.accessioned | 2022-12-21T05:07:30Z | - |
dc.date.available | 2022-12-21T05:07:30Z | - |
dc.date.created | 2022-09-19 | - |
dc.date.issued | 2007-12 | - |
dc.identifier.issn | 2234-2400 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/179203 | - |
dc.description.abstract | Background/Aims: This randomized, double-blind, phase III, multicenter trial was carried out to compare the efficacy and safety of revaprazan, a novel acid pump antagonist, with that of omeprazole in patients with more than one of gastric ulcers. Methods: Two hundred and ninety two subjects were randomized to 4∼8 weeks of treatment with either revaprazan 200 mg or omeprazole 20 mg. The primary efficacy parameter was the cumulative healing rate determined by endoscopy after 4 and 8 weeks of treatment, and the secondary efficacy parameter was an improvement rate of pain. Results: The intention-to-treat analysis revealed revaprazan and omeprazole to have similar cumulative healing rates (93.0% and 89.6%, respectively; p=0.3038). The per-protocol analysis revealed revaprazan and omeprazole to also have similar cumulative healing rates (99.1% and 100%, respectively; p= 0.3229). In both analyses, there were no significant differences in an improvement rate of pain between the two groups. Both drugs were well tolerated. Conclusions: Revaprazan has similar efficacy to omeprazole in the treatment of patients with gastric ulcer with a once a day application of revaprazan 200 mg or omeprazole 20 mg over a 4 to 8-week period. In terms of safety, revaprazan was well tolerated. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한소화기내시경학회 | - |
dc.title | 위궤양에 대한 레바프라잔 정제의 제3상 임상시험 | - |
dc.title.alternative | Phase III Clinical Trial of Revaprazan (Revanex?) for Gastric Ulcer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 최호순 | - |
dc.identifier.bibliographicCitation | Clinical Endoscopy, v.34, no.6, pp.312 - 319 | - |
dc.relation.isPartOf | Clinical Endoscopy | - |
dc.citation.title | Clinical Endoscopy | - |
dc.citation.volume | 34 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 312 | - |
dc.citation.endPage | 319 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001205387 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | 레바프라잔 | - |
dc.subject.keywordAuthor | 오메프라졸 | - |
dc.subject.keywordAuthor | 위궤양 | - |
dc.subject.keywordAuthor | 3상시험 | - |
dc.subject.keywordAuthor | Revaprazan | - |
dc.subject.keywordAuthor | Omeprazole | - |
dc.subject.keywordAuthor | Gastric ulcer | - |
dc.subject.keywordAuthor | Clinical trial phase III | - |
dc.identifier.url | https://www.kci.go.kr/kciportal/landing/article.kci?arti_id=ART001205387 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.